BioCina, a biologics contract development and manufacturing organization (CDMO) and NovaCina, a global fill-and-finish CDMO, have announced a partnership to offer integrated drug substance and drug product solutions for biologics developers. This will allow BioCina to provide fill/finish services while converting drug substances produced at its Adelaide, South Australia, facilities into drug product at NovaCina’s facilities in Perth, Australia. This collaboration aims to provide end-to-end biopharmaceutical manufacturing solutions.
BioCina specializes in CDMO services such as cell line development, process development, and current good manufacturing practice clinical and commercial manufacturing for microbial, plasmid DNA, and messenger RNA modalities.
